Successful collaborations among biopharmaceutical companies, patient advocacy organizations, and other key stakeholders help to de-risk drug development and can avoid potentially perilous roadblocks later on. This panel will explore how effective collaboration between the biopharmaceutical industry, the patient advocacy community, and other key stakeholders can speed the path to a cure and improve patient access – and share their insights and lessons learned about how to maximize the effectiveness and efficiency of these collaborations.